Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level822 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03257631 | A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | completed | Phase 2 | 53 | CelgeneINDUSTRY | 5 | Apr 16, 2024 | clinicaltrials |
| NCT06367569 | Evaluation of MRI of the Pineal Gland in Retinoblastoma(TRbFU) | completed | — | 607 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02654964 | Cancer Stem Cell High-Throughput Drug Screening Study | completed | Phase 1 | 9 | Swedish Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma(BrTK02) | completed | Phase 2 | 52 | Candel Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03925246 | Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas(REVOLUMAB) | completed | Phase 2 | 43 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT00596154 | Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma(PCNSL) | completed | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03454295 | Easing Psychosocial Burden for Informal Caregivers | completed | Early Phase 1 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03466450 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma(GEINOGLAS) | completed | Phase 1 / Phase 2 | 75 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04276194 | Vertebral Body Sparing Craniospinal Irradiation for Pediatric Patients With Cancer of the Central Nervous System | completed | N/A | 10 | Emory UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02962167 | Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT | completed | Phase 1 | 34 | Sabine Mueller, MD, PhDOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT03770468 | Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma | completed | — | 599 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
| NCT00342797 | Retinoblastoma Biomarker Study | completed | — | 2,136 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03712293 | ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy | completed | N/A | 9 | InSightecINDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT01505569 | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | completed | N/A | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT02869243 | A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients | completed | Phase 1 | 15 | StemgenINDUSTRY | 3 | Feb 16, 2024 | clinicaltrials |
| NCT04810182 | Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS | completed | — | 192 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT00704288 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | completed | Phase 2 | 222 | ExelixisINDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01661400 | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors(ASCR) | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 31, 2024 | clinicaltrials |
| NCT02206230 | Trial of Hypofractionated Radiation Therapy for Glioblastoma | completed | Phase 2 | 133 | AHS Cancer Control AlbertaOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT00928226 | Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases | completed | N/A | 56 | Stanford UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01811498 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | completed | Phase 1 / Phase 2 | 31 | Northwell HealthOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03616860 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma | completed | N/A | 14 | InSightecINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | completed | Phase 1 | 13 | Gregory K. Friedman, MDOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04552886 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | completed | Phase 1 | 17 | The Cooper Health SystemOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT01854554 | Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT) | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT03565367 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors | completed | Phase 1 | 9 | Daniel M. SpielmanOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT01502917 | Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy | completed | Phase 1 | 50 | Y-mAbs TherapeuticsINDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04264143 | CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas | completed | Phase 1 | 9 | Luca SzalontayOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02060890 | Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma(TGEN) | completed | — | 20 | University of California, San FranciscoOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02193347 | IDH1 Peptide Vaccine for Recurrent Grade II Glioma(RESIST) | completed | Phase 1 | 24 | Katy Peters, MD, PhDOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01957956 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT00588523 | Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma | completed | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03557372 | Mathematical Model-Adapted Radiation In Glioblastoma | completed | N/A | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02313272 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 16, 2024source: clinicaltrials